within Pharmacolibrary.Drugs.ATC.S;

model S01BA06
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.05,
    Cl             = 0.12 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 0.5 / 1000000,
    adminCount     = 1,
    Vd             = 0.0015,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Betamethasone is a synthetic glucocorticoid corticosteroid used for its anti-inflammatory and immunosuppressive effects. Its ophthalmic formulation (ATC S01BA06) is primarily indicated for the treatment of inflammatory and allergic conditions of the eye. It is approved and widely used today in topical ophthalmic formulations.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for adults after ocular (ophthalmic) administration, as there are no directly published population pharmacokinetic models for ophthalmic betamethasone. Parameters are adapted from systemic (oral/intravenous) administration as an approximation. No human PK model for ophthalmic betamethasone in literature.</p><h4>References</h4><ol><li><p>Asano, N, et al., &amp; Kawazu, K (2017). Penetration Route of the Selective Glucocorticoid Receptor Agonist SA22465 and Betamethasone into Rabbit Meibomian Gland Based on Pharmacokinetics and Autoradiography. <i>Drug metabolism and disposition: the biological fate of chemicals</i> 45(7) 826–833. DOI:<a href=&quot;https://doi.org/10.1124/dmd.117.075473&quot;>10.1124/dmd.117.075473</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28438780/&quot;>https://pubmed.ncbi.nlm.nih.gov/28438780</a></p></li><li><p>Salminen, L (1990). Review: systemic absorption of topically applied ocular drugs in humans. <i>Journal of ocular pharmacology</i> 6(3) 243–249. DOI:<a href=&quot;https://doi.org/10.1089/jop.1990.6.243&quot;>10.1089/jop.1990.6.243</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2290070/&quot;>https://pubmed.ncbi.nlm.nih.gov/2290070</a></p></li><li><p>Tajika, T, et al., &amp; Sakaki, H (2011). Pharmacokinetic features of difluprednate ophthalmic emulsion in rabbits as determined by glucocorticoid receptor-binding bioassay. <i>Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics</i> 27(1) 29–34. DOI:<a href=&quot;https://doi.org/10.1089/jop.2010.0106&quot;>10.1089/jop.2010.0106</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21182429/&quot;>https://pubmed.ncbi.nlm.nih.gov/21182429</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end S01BA06;
